[1] 陈燕, 陆振虞, CHEN Yan, LU Zhen-yu. 帕金森病发病机制的研究进展 [J]. 医学综述 2007.doi:10.3969/j.issn.1006-2084.2007.14.017
[2] 洪雁, 张本恕, HONG Yan, ZHANG Ben-shu. Parkin基因多态性与帕金森病遗传易患性关系的研究 [J]. 中国现代神经疾病杂志 2006.doi:10.3969/j.issn.1672-6731.2006.04.011
[3] 王洵, 刘燕, 肖艳, 张晓莺. 环境和生物因素在帕金森病发病中的作用 [J]. 临床神经病学杂志 2011.
[4] 李宝芹, 王玉凯, 宁玉萍, 谢安木, 刘焯霖. α-触核蛋白在帕金森病发病机制中作用的研究 [J]. 中国神经精神疾病杂志 2003.doi:10.3969/j.issn.1002-0152.2003.02.007
[5] 戚辰, 刘振国. 帕金森病发病机制研究进展:α-synuclein与氧化应激 [J]. 中国神经科学杂志 2004.
[6] 张庆云, 杨慧, 董晓东. 铁在帕金森病发病机制中的作用 [J]. 医学研究与教育 2012.
[7] 舒红格, 漆剑频, 朱文珍, 王承缘, 胡军武, 冯定义. 帕金森病脑铁沉积的定量研究 [J]. 华中科技大学学报（医学版） 2009.doi:10.3870/j.issn.1672-0741.2009.04.027
[8] 郭春彦, 陈忻, GUO Chun-yan, CHEN Xin. 铁与帕金森病关系研究进展 [J]. 中国实验动物学报 2011.doi:10.3969/j.issn.1005-4847.2011.04.020
[9] 姜宏, 谢俊霞. 脑内高铁在帕金森病病因中的作用 [J]. 中国神经科学杂志 2001.
[10] John H.Viles. Metal ions and amyloid fiber formation in neurodegenerative diseases. Copper, zinc and iron in Alzheimer's, Parkinson's and prion diseases [J]. Coordination chemistry reviews 2012, 19/20(19/20).
[11] Zheng, W., Monnot, A.D.. Regulation of brain iron and copper homeostasis by brain barrier systems: Implication in neurodegenerative diseases [J]. Pharmacology and Therapeutics: The Journal of the International Encyclopedia of Pharmacology and Therapeutics 2012, 2(2).
[12] Henryk Kozlowski, Marek Luczkowski, Maurizio Remelli, Daniela Valensin. [J]. Coordination chemistry reviews 2012.
[13] 朱爱琴. 帕金森病的发病机制及治疗进展 [J]. 青海医药杂志 2000, 30(07).
[14] Sleeman, I.J., Boshoff, E.L., Duty, S.. Fibroblast growth factor-20 protects against dopamine neuron loss in vitro and provides functional protection in the 6-hydroxydopamine-lesioned rat model of Parkinson's disease [J]. Neuropharmacology 2012, 7(7).
[15] Shiner, T., Seymour, B., Wunderlich, K., Hill, C., Bhatia, K.P., Dayan, P., Dolan, R.J.. Dopamine and performance in a reinforcement learning task: Evidence from Parkinson's disease [J]. Brain: A journal of neurology 2012, 6(6).
[16] Ooe H, Taira T, Iguchi Ariga SM, Ariga H. Induction of reactive oxygen species by bisphenol A and abrogation of bisphenol A-induced cell injury by DJ-1. [J]. Toxicological sciences: An official journal of the Society of Toxicology 2005, 1(1).
[17] Farrer M, Kachergus J, Forno L, Lincoln S, Wang DS, Hulihan M, Maraganore D, Gwinn Hardy K, Wszolek Z, Dickson D, Langston JW. Comparison of kindreds with parkinsonism and alpha-synuclein genomic multiplications. [J]. Annals of Neurology 2004, 2(2).
[18] KITADA T, ASAKAWA S, HATTORI N. Mutation in the parkin genecause autosomal recessive juvenile parkinsonism [J]. NATURE 1998, 392(6676).
[19] Boelmans, K., Holst, B., Hackius, M., Finsterbusch, J., Gerloff, C., Fiehler, J., Münchau, A.. Brain iron deposition fingerprints in Parkinson's disease and progressive supranuclear palsy [J]. Movement disorders 2012, 3(3).
[20] Jin, L., Wang, J., Jin, H., Fei, G., Zhang, Y., Chen, W., Zhao, L., Zhao, N., Sun, X., Zeng, M., Zhong, C.. Nigral iron deposition occurs across motor phenotypes of Parkinson's disease [J]. European journal of neurology: the official journal of the European Federation of Neurological Societies 2012, 7(7).
[21] OAKLEY R, COLLINGWOOD J F, DOBSON J. Individual dopaminergic neurons show raised iron levels in Parkinson disease [J]. NEUROLOGY 2007, 68(21).
[22] Lehmensiek V, Tan EM, Schwarz J, Storch A. Expression of mutant alpha-synucleins enhances dopamine transporter-mediated MPP+ toxicity in vitro. [J]. Neuroreport 2002, 10(10).
[23] Webb JL, Ravikumar B, Atkins J, Skepper JN, Rubinsztein DC. Alpha-Synuclein is degraded by both autophagy and the proteasome. [J]. The Journal of biological chemistry 2003, 27(27). |
